The immediate focus for Tissium will be the aggressive expansion of its commercial footprint within the US market. With COAPTIUM CONNECT already holding FDA authorization and being commercially available, the €60 million capital infusion is intended to fuel widespread adoption among surgeons and hospitals. This means establishing robust sales channels, increasing product awareness through clinical education, and building out distribution networks. Expect to see Tissium investing heavily in direct sales teams, attending major surgical conferences, and publishing more clinical data to support the benefits of its sutureless approach. The company will also need to navigate the complex reimbursement landscape in the US to ensure broader access for patients. The initial tranche of the EIB funding is expected to be drawn before the end of June 2026, providing an immediate boost to these efforts.
Image: courtesy of Thenextweb
Tissium Secures €60M to Accelerate US Rollout of Sutureless Nerve Repair System
Tissium, a Paris-based medtech firm, has successfully raised €60 million to expand the presence of its COAPTIUM CONNECT system in the United States. This funding, comprising a €30 million Series D2 round and a €30 million loan from the European Investment Bank (EIB), is earmarked for accelerating the commercialization of its FDA-cleared nerve glue, which offers a sutureless alternative to traditional nerve repair. The company's product, already commercially available in the US, aims to simplify peripheral nerve surgery and potentially improve patient outcomes by replacing intricate stitching with a light-cured adhesive.
Outlook
Background
The medical device industry, particularly in surgical innovation, is characterized by high research and development costs, stringent regulatory hurdles, and a slow adoption curve for new technologies. Tissium’s COAPTIUM CONNECT system represents a significant departure from the established surgical practice of suturing (stitching) nerves, a technique that has been standard for decades. Peripheral nerve repair, often required after trauma, involves reconnecting very delicate nerve endings, a procedure demanding high precision and skill. Traditional suturing can sometimes cause additional trauma to the nerve tissue, potentially affecting recovery.
Tissium's technology uses a biomorphic, programmable polymer that is applied to the nerve endings and then cured with light, creating a flexible, strong, and biocompatible seal. The product received FDA De Novo authorization on June 24, 2025, a specific regulatory pathway for novel low-to-moderate risk devices that lack a predicate device. This authorization was a critical milestone, establishing COAPTIUM CONNECT as the first and only FDA-cleared sutureless system for atraumatic peripheral nerve coaptation. The subsequent €60 million funding, announced on June 24, 2026, reflects investor confidence in the product's market potential following this regulatory clearance.
Precedents
Disruptive medical technologies often follow a similar trajectory: initial scientific breakthrough, rigorous testing, regulatory approval, and then the challenging phase of market adoption. Historically, innovations that simplify complex surgical procedures or improve patient outcomes tend to gain traction, though often slowly. For instance, the transition from open surgery to laparoscopic (minimally invasive) techniques took decades to become widespread, despite clear benefits. Similarly, advancements in surgical adhesives and sealants have gradually replaced or augmented sutures and staples in various fields, from vascular surgery to general soft tissue repair.
Companies introducing novel devices must overcome surgeon skepticism, ingrained habits, and the need for new training. They also face the hurdle of proving long-term efficacy and cost-effectiveness compared to existing methods. Securing substantial funding, especially from institutions like the European Investment Bank, signals a level of due diligence and strategic backing that often precedes successful market penetration for medtech 'champions.' The EIB's pattern of supporting European deeptech and medtech companies, as seen with Protembis and Ryvu Therapeutics, suggests a belief in Tissium's potential to become a leader in its niche.
This funding and the expanded US market entry for Tissium's sutureless nerve glue could mark a significant shift in how peripheral nerve injuries are treated. For patients, the potential benefits include less scarring, reduced risk of nerve damage from sutures, and potentially faster or more complete recovery. The 'atraumatic' nature of the repair method suggests a gentler approach to delicate nerve tissue, which is crucial for functional recovery. For surgeons, the technology could streamline a technically demanding procedure, potentially reducing operating times and improving consistency of outcomes.
Beyond the operating room, this development challenges the traditional training and established practices in microsurgery. If successful, it could pave the way for other sutureless or adhesive-based solutions in different areas of reconstructive surgery. The investment also validates the potential of biomorphic polymer technology, attracting further research and development into advanced biomaterials. For the medtech investment community, Tissium's progress offers a case study in how to bring truly novel, high-impact medical devices from concept to commercial viability, especially those requiring a De Novo FDA pathway.
Scenarios
AnalysisOne possible outcome is that Tissium's COAPTIUM CONNECT achieves rapid adoption in the US market, driven by strong clinical data and positive surgeon experiences. This could lead to a new standard of care for peripheral nerve repair, particularly in trauma centers and specialized surgical practices. Increased adoption would likely attract further investment, potentially enabling Tissium to expand into other therapeutic areas or geographies where its polymer platform could be applied.
Conversely, Tissium could face significant challenges in overcoming the inertia of established surgical practices. Surgeons may be hesitant to adopt a new, radically different technique without extensive long-term data, even with FDA clearance. Payer reimbursement policies, which often lag behind innovation, could also slow uptake if hospitals face difficulty getting procedures covered. In this scenario, adoption might be slower and more localized, requiring Tissium to invest even more heavily in education and advocacy to demonstrate the value proposition.
A third outcome could see Tissium's technology finding a specific niche within nerve repair, such as in cases where traditional suturing is particularly difficult or carries higher risks. This could lead to moderate but steady growth, establishing the technology as a valuable tool in the surgeon's arsenal without completely displacing existing methods. The company may also face competitive responses from larger medical device manufacturers who could develop their own adhesive solutions or improve existing suturing techniques.
Timeline
Frequently Asked Questions
Discussion
Be the first to share your thoughts.